quinoxalines has been researched along with fm1 43 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, X; Mennerick, S; Moulder, KL; Olney, JW; Taylor, AA | 1 |
| Avegno, EM; Borgkvist, A; Hen, R; Kheirbek, MA; Sonders, MS; Sulzer, D; Wong, MY | 1 |
2 other study(ies) available for quinoxalines and fm1 43
| Article | Year |
|---|---|
Physiological activity depresses synaptic function through an effect on vesicle priming.
Topics: 2-Amino-5-phosphonovalerate; Action Potentials; Animals; Animals, Newborn; Dose-Response Relationship, Drug; Electric Stimulation; Excitatory Amino Acid Antagonists; Hippocampus; Immunohistochemistry; Microscopy, Electron, Transmission; Neural Inhibition; Neurons; Organ Culture Techniques; Patch-Clamp Techniques; Potassium Chloride; Pyridinium Compounds; Quaternary Ammonium Compounds; Quinoxalines; Rats; Synapses; Synaptic Transmission; Synaptic Vesicles; Vesicular Glutamate Transport Protein 1 | 2006 |
Loss of Striatonigral GABAergic Presynaptic Inhibition Enables Motor Sensitization in Parkinsonian Mice.
Topics: Adrenergic Agents; Animals; Bacterial Proteins; Channelrhodopsins; Corpus Striatum; Disease Models, Animal; Dopamine; Excitatory Amino Acid Antagonists; GABA Agents; GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Inhibitory Postsynaptic Potentials; Luminescent Proteins; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Pyridinium Compounds; Quaternary Ammonium Compounds; Quinoxalines; Substantia Nigra | 2015 |